OpenResearchAlpha

Blood Journal · 12 Nov 2026

Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR

Piyanuch Kongtimh-index 21, Andrew Jay Portuguese, Roni Shouval, Soyoung Kim, Andrew Peterson, Mariam Allbee-Johnson, Temitope Oloyede, Brent R. Logan, Hany Elmariah, Lori S Muffly, Mark B. Juckett, Michael R Grunwald, Mariam T Nawas, Nelli Bejanyan, Tania Jain, Veronika Bachanova, Xia Bi, Ryan J Stubbins, Sairah Ahmed, Seth J. Rotz, Annie Im, Shatha Farhan, Poorva Bindal, Reena V Jayani Kosarzycki, Michelle L Schoettler, Hélène M. Schoemans, Betty K. Hamilton, Rachel Phelan, Ryotaro Nakamura, Betul Oran, Saurabh Chhabra, Edward Stadtmauer, Brandon Nuechterlein, Rebecca Higgins, Mohamed L Sorror, Amy Moskop, Arnon Nagler, Bipin N. Savani, Wael Saber, Bart L Scott, Stefan O. Ciureah-index 18

0
Citations
no database records one yet
0
Citations in 2026
so far
21
Leading author's h-index
Piyanuch Kongtim, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

The optimal reduced-intensity conditioning (RIC) regimen for older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (AHCT) remains undefined. We utilized CIBMTR registry data (2013-2022) to compare five common fludarabine-based regimens in 11,731 patients aged ≥50 years: fludarabine combined with 2 days of busulfan (FB2), melphalan 100 mg/m² (FM100), melphalan 140 mg/m² (FM140), or 2 Gy TBI with (FCT) or without (FT) cyclophosphamide. Using propensity score inverse probability weighting and Bayesian Additive Regression Trees (BART), we found that Fludarabine-melphalan (FM) regimens demonstrated superior long-term survival. Although FM140, FCT, and FT showed higher early mortality (≤6 months) than FB2 (P=.036), both FM100 (HR 0.79) and FM140 (HR 0.77) achieved significantly better late (> 6 months) overall survival (OS), outperforming all other regimens (P<.0001). In the 2019-2022 cohort, FM100, FM140, and FCT provided improved disease-free survival (DFS) relative to FB2. Specifically, FM100 yielded superior DFS compared to FCT (P=0.002) and FT (P=0.007). FM-based conditioning consistently resulted in lower relapse rates (P<.0001) and improved late GVHD-free/relapse-free survival. While FM regimens faced higher early non-relapse mortality (NRM), this impact did not persist beyond 6 months. BART analysis confirmed that these survival and relapse benefits remained robust across various patient comorbidities. In conclusion, FM100 and FM140 provide superior long-term survival and DFS for older patients with AML/MDS by providing potent anti-leukemic activity that offsets higher early toxicity. These findings support FM-based RIC as the preferred conditioning platform for this population, regardless of baseline comorbidities.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Piyanuch Kongtim has the highest h-index among the authors (21).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (41)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.